Mitosis-targeted anti-cancer therapies: where they stand
Open Access
- 18 October 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cell Death & Disease
- Vol. 3 (10), e411
- https://doi.org/10.1038/cddis.2012.148
Abstract
The strategy of clinically targeting cancerous cells at their most vulnerable state during mitosis has instigated numerous studies into the mitotic cell death (MCD) pathway. As the hallmark of cancer revolves around cell-cycle deregulation, it is not surprising that antimitotic therapies are effective against the abnormal proliferation of transformed cells. Moreover, these antimitotic drugs are also highly selective and sensitive. Despite the robust rate of discovery and the development of mitosis-selective inhibitors, the unpredictable complexities of the human body’s response to these drugs still herald the biggest challenge towards clinical success. Undoubtedly, the need to bridge the gap between promising preclinical trials and effective translational bedside treatment prompts further investigations towards mapping out the mechanistic pathways of MCD, understanding how these drugs work as medicine in the body and more comprehensive target validations. In this review, current antimitotic agents are summarized with particular emphasis on the evaluation of their clinical efficacy as well as their limitations. In addition, we discuss the basis behind the lack of activity of these inhibitors in human trials and the potential and future directions of mitotic anticancer strategies.Keywords
This publication has 134 references indexed in Scilit:
- A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinomaGynecologic Oncology, 2012
- Caspase-3-mediated degradation of condensin Cap-H regulates mitotic cell deathCell Death & Differentiation, 2010
- A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trialInvestigational New Drugs, 2010
- Pharmacologic Inhibition of the Anaphase-Promoting Complex Induces A Spindle Checkpoint-Dependent Mitotic Arrest in the Absence of Spindle DamageCancer Cell, 2010
- A pediatric phase I trial and pharmacokinetic study of ispinesib: A Children's Oncology Group phase I consortium studyPediatric Blood & Cancer, 2010
- A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomasCancer Chemotherapy and Pharmacology, 2009
- Evidence that Mitotic Exit Is a Better Cancer Therapeutic Target Than Spindle AssemblyCancer Cell, 2009
- Correcting aberrant kinetochore microtubule attachments: an Aurora B-centric viewCurrent Opinion in Cell Biology, 2009
- Compartmentalized Phosphorylation of IAP by Protein Kinase A Regulates CytoprotectionMolecular Cell, 2007
- Molecular mechanisms of drug resistanceThe Journal of Pathology, 2005